You just read:

New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

News provided by

Sanofi

Sep 30, 2019, 10:30 ET